Publication | Closed Access
An in vivo evaluation of the immunosuppressive action of bleomycin.
15
Citations
0
References
1972
Year
New Antineoplastic AntibioticImmunologyImmunotherapyDrug ResistanceDba/2 → Balb/cGraft SurvivalGraft Rejection TimesCell TransplantationAntimicrobial ResistanceTransplantationImmunosuppressive ActionPharmacologyTransplant RejectionAntibioticsImmunosuppressive TherapyImmunomodulationImmunosuppressionMedicineGraft Rejection
The new antineoplastic antibiotic, bleomycin, was evaluated in a non- H-2 allograft system (DBA/2 → BALB/c) for immunosuppressive action. At high doses, the drug significantly altered graft rejection times. The high mortality and severe debility at these doses, however, suggest that the prolonged allograft survival times were not mediated by specific immunosuppression.